From Wikipedia, the free encyclopedia

Zoetis Inc.
Founded1952; 71 years ago (1952)
HeadquartersParsippany, New Jersey, U.S.
Area served
Key people
Kristin Peck (CEO)
RevenueIncrease US$8.08 billion (2022)
Increase US$2.92 billion (2022)
Increase US$2.11 billion (2022)
Total assetsIncrease US$14.9 billion (2022)
Total equityDecrease US$4.41 billion (2022)
Number of employees
c. 13,800 (Dec 2022)
Footnotes / references

Zoetis Inc. (/zō-EH-tis/[3]) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.[4][3][5] The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue.[4] Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index.[6]


1950s to 2000s[edit]

Zoetis building in Exton, PA

In the 1950s, Pfizer began research on several drugs, including oxytetracycline, which was found to be effective in livestock.[7] In 1952, the Pfizer Agriculture Division opened a 732-acre research and development facility in Terre Haute, Indiana, called Vigo.[7][8] By 1988 the division was renamed Pfizer Animal Health.[7]

The 1995 acquisition of Norden Laboratories from GlaxoSmithKline expanded Pfizer's animal health division into small animal care, including domestic pets.[7] Secondary research and development centres were opened in Kalamazoo, Michigan, in 2003.[7] In the same year, Pfizer acquired Pharmacia Corporation for US$60 billion in stock options.[9] Between 2007 and 2011, the company acquired Embrex Inc, Catapult Genetics, Bovigen, Wyeth, Fort Dodge Animal Health, Vetnex Animal Health Ltd, Synbiotics Corporation, Microtek, King Pharmaceuticals, and Alpharma.[7]

2010s to present[edit]

Plans to break away Pfizer Animal Health into a separate company were officially announced in 2012.[10][3] The new firm was named Zoetis in allusion to the Latin-derived zoological term zoetic, meaning "pertaining to life".[3]

Zoetis Inc.'s revenues exceeded $4.2 billion in 2011 and $4.34 billion in 2012.[11][12][3] The animal health industry worldwide is an estimated US$22 billion industry.[3]

On May 22, 2013, The Wall Street Journal reported that Pfizer planned to sell its majority stake in the company.[12] According to the report, shareholders will have the option to swap their Pfizer shares for Zoetis shares.[12] The sell-off of Zoetis is consistent with Pfizer's recent decision to shed other non-pharmaceuticals subsidiaries in an effort to save costs, raise capital, and pay off debt. The company has announced that JPMorgan Chase, Bank of America, Merrill Lynch, Goldman Sachs & Co., and Morgan Stanley will be the lead underwriters.[13][12]

In November 2014, activist investor Bill Ackman disclosed that Pershing Square Capital Management had taken an 8.5% stake in the company, amassing approximately 41.8 million shares, causing the share price to hit its highest price since the IPO.[14] On 17 November, the company announced it would acquire a portfolio of pet drugs from Abbott Laboratories for approximately $255 million.[15]

2012: IPO[edit]

Records show that Pfizer officially filed for registration of a Class A stock with the U.S. Securities and Exchange Commission on August 10, 2012.[7][16] Zoetis' IPO on February 1, 2013 sold 86.1 million shares for US$ 2.2 billion.[17] Shares sharply rose 19% by the end of the trading day to $35.01 a share, up from $26.[3] At the time, it was the largest IPO from a U.S. company since Facebook's $16 billion IPO on May 18, 2012.[18] Pfizer retained 414 million Class B shares giving it an 83% controlling stake in the firm.[19][2] Stock investors were attracted to the steep profit margin in proportion to revenue and consumer confidence in potential future growth of the subsidiary.[3] The offering's lead underwriters were JPMorgan Chase, Bank of America Merrill Lynch and Morgan Stanley.[17] Most of the money raised through the IPO was used to pay off existing Pfizer debt.[3]


In November 2015, the company announced it would acquire a developer of aquaculture treatments and diseases, Pharmaq, for $765 million.[20][21] In 2017, Zoetis acquired Ireland-based Nexvet, a company with a biologics focused technology and product candidate pipeline.[22]

In May 2018, the company announced its intention to acquire Abaxis for $1.9 billion in cash.[23]

In August 2021, Zoetis announced it would buy Jurox, increasing the business' presence in New Zealand, the US, Canada and the UK.[24]

In June 2022, Zoetis acquired Basepaws, a privately held genetics company, to strengthen its portfolio of precision animal health solutions.[25]


Twenty-eight sites in 11 countries make up Zoetis manufacturing network, each facility designed to meet chemical and infectious agent safety regulatory requirements. Many R&D operations are co-located with manufacturing sites, a collaboration that allows bringing new products to market faster. Zoetis builds on six-decade Pfizer history and aims for high-tech innovative manufacturing technologies. Zoetis products include:[26]


  1. ^ "Zoetis Inc. 2022 Annual Report Form (10-K)". U.S. Securities and Exchange Commission. 14 February 2023. Retrieved 14 February 2023.
  2. ^ a b DIETERICH, CHRIS (31 January 2013). "Zoetis Raises $2.2 Billion in IPO - WSJ.com". The Wall Street Journal. New York. Retrieved 1 February 2013.
  3. ^ a b c d e f g h i "Shares of animal health company Zoetis soar in IPO". CBS News. New York. 1 February 2013. Retrieved 1 February 2013.
  4. ^ a b "Zoetis Inc, Form 10-K, Annual Report, Filing Date Feb 15, 2018" (PDF). secdatabase.com. Retrieved 26 April 2018.
  5. ^ "Zoetis raises about $2.2 billion in IPO". The Associated Press. New York: Yahoo!. 1 February 2013. Retrieved 1 February 2013.
  6. ^ Volkman, Eric (17 June 2013). "Zoetis to Join S&P 500; First Horizon National, QLogic Moved to New Indices -". The Motley Fool.
  7. ^ a b c d e f g "Form S-1". WASHINGTON, D.C: U.S. Securities and Exchange Commission. 10 August 2012. Retrieved 2 February 2013.
  8. ^ "Pfizer Buys 732 Acre Vigo Chemical Plant". Chicago Daily Tribune. 17 July 1958. p. 1. Retrieved 2 February 2013.
  9. ^ Frank, Robert; Hensley, Scott (15 July 2002). "Pfizer to Buy Pharmacia For $60 Billion in Stock". The Wall Street Journal. Retrieved 2 February 2013.
  10. ^ "Zoetis Inc, Form S-1/A, Filing Date Oct 11, 2012". secdatabase.com. Retrieved 26 April 2018.
  11. ^ "Zoetis Inc, Form 10-K, Annual Report, Filing Date Mar 28, 2013" (PDF). secdatabase.com. Retrieved 26 April 2018.
  12. ^ a b c d Loftus, Peter (22 May 2013). "Pfizer to Spin Off Remaining Zoetis Stake". The Wall Street Journal. Retrieved 27 May 2013.
  13. ^ "Zoetis Inc, Form 425, Filing Date May 23, 2013" (PDF). secdatabase.com. Retrieved 26 April 2018.
  14. ^ Chen, Caroline (11 November 2014). "Ackman's Pershing Square Takes Stake in Drugmaker Zoetis". Bloomberg.
  15. ^ "Zoetis Inc, Form 8-K, Current Report, Filing Date Nov 17, 2014". secdatabase.com. Retrieved 26 April 2018.
  16. ^ "Zoetis Inc, Form S-1/A, Filing Date Jan 29, 2013". secdatabase.com. Retrieved 26 April 2018.
  17. ^ a b J. DE LA MERCED, MICHAEL (1 February 2013). "Shares of Zoetis Surge on Debut". New York Times. New York. Retrieved 1 February 2013.
  18. ^ "Facebook, Form 424B4, Filing Date May 18, 2012". secdatabase.com. Retrieved 27 April 2018.
  19. ^ "Zoetis, Form S-1/A, Filing Date Jan 29, 2013". secdatabase.com. Retrieved 27 April 2018.
  20. ^ "Zoetis, Form 8-K, Current Report, Filing Date Nov 2, 2015". secdatabase.com. Retrieved 27 April 2018.
  21. ^ "Zoetis Purchasing PHARMAQ for $765M". 3 November 2015.
  22. ^ Vinluan, Frank (13 April 2017). "Zoetis Builds on Biologics Pipeline with $85M Nexvet Acquisition". Xconomy. New York, NY, USA. Retrieved 9 April 2018.
  23. ^ "Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 billion". 16 May 2018 – via uk.reuters.com.
  24. ^ "Zoetis to Acquire Jurox, a Leading Provider and Manufacturer of Livestock and Companion Animal Products".
  25. ^ "Zoetis Completes Acquisition of Basepaws, an Innovative Leader in Petcare Genetics, to Strengthen its Portfolio of Precision Animal Health Solutions". Business Wire. 22 June 2022. Retrieved 22 July 2022.
  26. ^ Pfizer Animal Health Products Archived 22 July 2012 at the Wayback Machine

External links[edit]

  • Official website
  • Business data for Zoetis: